➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
McKinsey
Dow
Moodys
McKesson

Last Updated: April 19, 2021

DrugPatentWatch Database Preview

DARZALEX Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Tradename: DARZALEX
Patents:20
Applicants:1
BLAs:2
Suppliers: see list1
Recent Clinical Trials: See clinical trials for DARZALEX
Recent Clinical Trials for DARZALEX

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Omar NadeemPhase 2
Charite University, Berlin, GermanyPhase 2
Deutsches Rheuma-Forschungszentrum Berlin (DRFZ)Phase 2

See all DARZALEX clinical trials

Pharmacology for DARZALEX
Ingredient-typeAntibodies, Monoclonal
Mechanism of ActionCD38-directed Antibody Interactions

Patent Text Search: US Patents for DARZALEX

These patents were identified by searching patent claims
Glossary
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Janssen Biotech DARZALEX daratumumab INJECTABLE;INJECTION 761036 001 2015-11-16   Start Trial AbbVie Stemcentrx LLC (North Chicago, IL) 2033-02-08 RX Orphan search
Janssen Biotech DARZALEX daratumumab INJECTABLE;INJECTION 761036 001 2015-11-16   Start Trial Advenchen Pharmaceuticals, LLC (Moorpark, CA) 2035-05-04 RX Orphan search
Janssen Biotech DARZALEX daratumumab INJECTABLE;INJECTION 761036 001 2015-11-16   Start Trial The United States of America, as represented by the Secretary, Department of Health and Human Services (Washington, DC) Janssen Biotech, Inc. (Spring House, PA) 2034-06-16 RX Orphan search
Janssen Biotech DARZALEX daratumumab INJECTABLE;INJECTION 761036 001 2015-11-16   Start Trial Mayo Foundation for Medical Education and Research (Rochester, MN) 2034-06-16 RX Orphan search
Janssen Biotech DARZALEX daratumumab INJECTABLE;INJECTION 761036 001 2015-11-16   Start Trial Cipla Limited (Mumbai, IN) 2036-06-30 RX Orphan search
Janssen Biotech DARZALEX daratumumab INJECTABLE;INJECTION 761036 001 2015-11-16   Start Trial ALX ONCOLOGY INC. (Burlingame, CA) 2035-08-07 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Express Scripts
Johnson and Johnson
Baxter
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2021 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2021 - 2022
 NCE-1 Patent Challenge Dates 2021 - 2022
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2021, www.DrugPatentWatch.com.

Links

Follow DrugPatentWatch:

  DrugPatentWatch Linkedin Group